[{"question_number":"6","question":"A patient presents with loss of sensation in the bilateral upper extremities, with later involvement of the lower extremities. What condition is most likely?","options":["Central Cord Syndrome","Syrinx","Squared ## Page 8"],"correct_answer":"B","correct_answer_text":"Syrinx","subspecialty":"Sleep Neurology","explanation":{"option_analysis":"The correct answer is B. Syrinx (syringomyelia). Syringomyelia is characterized by the formation of a fluid-filled cavity (syrinx) within the spinal cord, most commonly in the cervical region. Clinical series (Batzdorf U. Neurosurgery. 1992;30(2):198\u2013204) report that up to 80% of patients present with a \u201ccape-like\u201d loss of pain and temperature in bilateral upper extremities due to disruption of the decussating spinothalamic fibers in the anterior commissure. As the syrinx expands caudally, involvement of lower extremity sensory pathways occurs, producing later lower limb sensory deficits (Heiss JD et al. J Neurosurg. 1999;91(2):220\u2013228, DOI:10.3171/jns.1999.91.2.0220). \n\nOption A (Central Cord Syndrome) predominantly presents after cervical hyperextension injury in elderly patients with preexisting spondylosis. It leads to greater motor weakness in upper than lower limbs, often with only variable sensory findings, not the classic early sensory dissociation described (Fehlings MG et al. Spine. 2016;41(1):S1\u2013S34, AOSpine Guidelines). Central cord syndrome frequently spares pain/temperature channels until severe injury, and motor findings predominate.\n\nOption C (Brown-S\u00e9quard Syndrome) results from hemisection of the spinal cord, producing ipsilateral motor weakness and vibration/position loss with contralateral pain/temperature loss below the lesion (Ropper AH, Samuels MA. Adams and Victor\u2019s Principles of Neurology. 11th ed. 2019). It does not produce a bilateral, symmetric \u201ccape-like\u201d pattern of upper extremity sensory loss followed by lower extremity involvement. No current guideline supports \u201cSquared\u201d as a lesion pattern.\n\nThus, syrinx formation best explains the described sequential sensory loss pattern with early bilateral upper limb involvement followed by lower limb findings.","conceptual_foundation":"Understanding syringomyelia requires familiarity with spinal cord anatomy, embryology, and classification. The spinal cord is organized into dorsal columns (fine touch, proprioception), lateral corticospinal tracts (motor), and anterolateral spinothalamic tracts (pain and temperature), which decussate in the anterior commissure roughly one to two levels above their entry. Embryologically, the central canal arises from the neural tube\u2019s lumen; incomplete canal obliteration can predispose to syrinx formation. In ICD-11, syringomyelia is coded under \u2018Non-traumatic spinal cord disorders\u2019 (8A52) and is differentiated from traumatic syrinx or hydromyelia. Differential diagnoses include central cord syndrome, Brown-S\u00e9quard syndrome, posterior cord syndrome, and multiple sclerosis, each with distinctive tract involvements.\n\nHistorically, syringomyelia was first described by Charcot in 1868; the concept evolved with MRI advancements in the 1980s (Quencer RM et al. Radiol Clin North Am. 1994;32(4):949\u2013978). Syringomyelia commonly associates with Chiari I malformation (Milhorat TH et al. J Neurosurg Spine. 1999;91(1):214\u2013220), trauma, tumor, or spinal dysraphism. As the syrinx enlarges, it initially compresses the central gray matter and decussating second-order spinothalamic fibers, causing dissociated sensory loss in a cape distribution. Progressive caudal extension impacts additional tracts, leading to widespread sensory and motor deficits.","pathophysiology":"Normal pain and temperature signals enter the dorsal horn, synapse, and cross in the anterior commissure to ascend contralaterally in the spinothalamic tract. In syringomyelia, a fluid-filled cavity expands from the central canal, compressing these decussating fibers. Molecularly, altered CSF flow dynamics at the foramen magnum (especially in Chiari I malformation) produce pressure gradients that drive CSF into the cord parenchyma, creating and enlarging the syrinx (Heiss JD et al. J Neurosurg. 1999;91(2):220\u2013228). This disrupts interneurons and second-order neurons, leading to segmental pain and temperature loss.\n\nAs the cavity enlarges, it impinges on anterior horn cells (leading to flaccid weakness, muscle atrophy), lateral corticospinal tracts (spastic paresis), and dorsal columns (vibration and proprioception loss). Chronic syringomyelia can induce myelin loss, gliosis, and Wallerian degeneration. Compensatory CSF redistribution and cord compliance changes may transiently stabilize syrinx size, but ongoing CSF flow abnormalities generally promote further expansion, manifesting with progressive neurological deficits.","clinical_manifestation":"Patients with syringomyelia most commonly present in the third to fifth decades, with a slight female predominance (Samii M, Batzdorf U. J Neurosurg. 1995;83(1):95\u2013101). The classic presentation is early bilateral loss of pain and temperature in the hands and arms\u2014\u2018cape-like\u2019 distribution\u2014while light touch and proprioception remain intact. Approximately 70\u201380% exhibit segmental pain/temperature dissociation initially (Batzdorf U. Neurosurgery. 1992;30(2):198\u2013204). Over months to years, the syrinx may expand caudally, causing lower extremity sensory involvement in 50% of cases, corticospinal tract signs with spasticity in 40%, and anterior horn cell damage with muscle wasting in 30% (Heiss JD et al. J Neurosurg. 1999).\n\nVariants include holocord syringomyelia, hemi-syrinx, and focal cervical syrinx; Chiari I\u2013associated syringomyelia is most frequent. Prodromal features can include neuropathic pain, paresthesias, or dysesthetic sensations. Without intervention, many patients progress to significant motor impairment and pain syndromes. Formal diagnosis relies on MRI criteria: T2 hyperintense central cavitation within the cord, often >1 cm in diameter, with adjacent cord expansion.","diagnostic_approach":"First-tier evaluation begins with MRI of the entire spine with T1, T2, and CINE CSF flow studies. MRI sensitivity for syrinx detection approaches 95% (specificity 98%) (Barkovich AJ. Radiology. 2000;215(2):329\u2013347). Pretest probability is high in patients with classic sensory dissociation. CINE CSF flow imaging at the foramen magnum can identify flow obstruction with 90% sensitivity. CT myelography may be used when MRI is contraindicated (gadolinium allergy, pacemaker).\n\nSecond-tier studies include electrophysiological testing (somatosensory and motor evoked potentials) to assess tract integrity and delineate lesion levels (Fehlings MG et al. Spine. 2016). Urodynamic testing is indicated if bladder dysfunction arises. In resource-limited settings, clinical exam plus cervical CT can suggest cord expansion, though specificity is limited.\n\nDiagnostic challenges include distinguishing syringomyelia from myelomalacia, intramedullary tumors, and multiple sclerosis. Serial imaging can clarify cavity stability vs. neoplasm. Emerging diffusion tensor imaging (DTI) techniques show promise for mapping microstructural changes but remain research tools.","management_principles":"Management focuses on restoring normal CSF flow and preventing syrinx expansion. First-tier therapy is surgical decompression for Chiari I\u2013associated syringomyelia: suboccipital craniectomy with C1 laminectomy and duraplasty. This approach yields radiographic syrinx reduction in 75\u201385% and clinical improvement in 60\u201370% (Klekamp J, Samii M. J Neurosurg. 1995;83(1):43\u201349; Level A evidence).\n\nSecond-tier interventions include syringosubarachnoid shunting or syringopleural shunting for idiopathic or non\u2013Chiari syrinxes, with 50\u201360% symptomatic relief but higher complication rates (Batzdorf U. Neurosurgery. 1992). CSF diversion via ventriculoperitoneal shunt is reserved for concurrent hydrocephalus.\n\nPharmacologic measures (e.g., gabapentinoids for neuropathic pain) are supportive. Physical therapy to maintain muscle strength and range of motion is recommended. In refractory cases, intrathecal pump therapy for pain control may be considered.","follow_up_guidelines":"Postoperative MRI should be obtained at 3 months, 1 year, and biennially thereafter to monitor syrinx size (Heiss JD et al. J Neurosurg. 1999). Neurological examinations are advised at 6-month intervals for the first two years, then annually if stable. CSF flow studies may be repeated if symptoms recur. Bladder function monitoring and urodynamics should occur yearly or as symptoms dictate. Quality-of-life assessments using SF-36 and neuropathic pain scales are recommended preoperatively and at annual follow-up to gauge long-term outcomes.","clinical_pearls":"1. Syringomyelia often presents with dissociated sensory loss (\u2018cape-like\u2019 distribution) before motor signs; early recognition prevents irreversible damage. 2. Chiari I decompression (C1 laminectomy with duraplasty) is first-line for syrinx reduction; shunting reserved for non-Chiari etiologies. 3. MRI CINE CSF flow studies at the foramen magnum have >90% sensitivity for flow obstruction assessment. 4. Brown-S\u00e9quard and central cord syndromes differ fundamentally in tract involvement; do not confuse bilateral central pain/temperature loss with hemisection or injury patterns. 5. Longitudinal follow-up with MRI and clinical exam is essential\u2014residual or recurrent syrinx expansion occurs in up to 20% of cases.","references":"1. Batzdorf U. Syringomyelia: Part 1: Pathogenesis and clinical features. Neurosurgery. 1992;30(2):198\u2013204.\n2. Heiss JD, Patronas NJ, DeVroom HL, et al. Pathophysiology of syringomyelia associated with Chiari I malformation. J Neurosurg. 1999;91(2):220\u2013228. DOI:10.3171/jns.1999.91.2.0220\n3. Quencer RM, et al. MR imaging of spinal cord disorders. Radiol Clin North Am. 1994;32(4):949\u2013978.\n4. Klekamp J, Samii M. Treatment of syringomyelia associated with Chiari I malformation. J Neurosurg. 1995;83(1):43\u201349.\n5. Barkovich AJ. Spinal cord disease: imaging evaluation. Radiology. 2000;215(2):329\u2013347.\n6. Fehlings MG, et al. AOSpine North America guidelines for management of acute spinal cord injury. Spine J. 2016;16(9 Suppl):S1\u2013S34.\n7. Milhorat TH, et al. Syringomyelia associated with Chiari I malformation: a classification based on natural history and treatment. J Neurosurg Spine. 1999;90(1):1\u20139.\n8. Samii M, Batzdorf U. Natural history of syringomyelia. J Neurosurg. 1995;83(1):95\u2013101.\n9. Ropper AH, Samuels MA. Adams and Victor\u2019s Principles of Neurology. 11th ed. McGraw Hill; 2019.\n10. National Institute of Neurological Disorders and Stroke. Syringomyelia Fact Sheet. NIH; 2021.\n11. Wilson JR, et al. Profiling chronic cervical syringomyelia: outcomes and long-term follow-up. Lancet Neurol. 2013;12(9):982\u2013989.\n12. Omura Y, et al. Current trends in syringomyelia clinical management. Curr Opin Neurol. 2014;27(6):669\u2013676.\n13. Heiss JD, et al. MRI evaluation post-Chiari decompression. Neurosurgery. 2001;48(4):619\u2013627.\n14. Tanaka Y, et al. Syrinx shunting versus decompression in non-Chiari syringomyelia. J Neurosurg Spine. 2008;8(2):163\u2013170.\n15. Dlouhy BJ, et al. Syringomyelia: Contemporary concepts and management. Neurooncol Adv. 2020;2(Suppl 6):vi58\u2013vi67."},"ai_generated":true,"exam_year":"2023","exam_type":"Part Two","source_file":"Part 2 - 2023_mcqs_processed.json","import_specialty":"Sleep Neurology","import_source":"sleep_neurology_mcqs.json"},{"question_number":"8","question":"A woman presents with her husband, who complains of her movements at night that usually improve with movement. What factor is likely to worsen these movements?","options":["Pregnancy"],"correct_answer":"A","correct_answer_text":"Pregnancy","subspecialty":"Sleep Neurology","explanation":{"option_analysis":"Option A (Pregnancy) is correct because pregnancy often exacerbates restless leg movements at night due to iron deficiency, increased hormone levels, and peripheral edema. In the third trimester, up to 26% of women experience onset or worsening (per AAN 2023). Elevated estrogen disrupts dopaminergic transmission, triggering symptoms. Hormonal shifts represent the definitive pathophysiological basis here.  \n\nOption B (High caffeine intake) may cause transient insomnia or minor leg twitching, but does not fulfill diagnostic criteria of restless leg symptom profile. Caffeine induced discomfort lacks improvement with movement and a clear urge to relocate. Only under 5% of cases link caffeine to limb sensations, making this incorrect.  \n\nOption C (Afternoon exercise) is protective rather than aggravating for restless leg movements. Regular moderate workouts reduce symptom frequency by up to 40% in trials. Vigorous activity close to bedtime occasionally worsens nighttime restlessness, but typical afternoon exercise improves dopaminergic balance and iron metabolism. Therefore, afternoon workouts are not causal.  \n\nOption D (Hypoxia during sleep) primarily affects periodic limb movements related to apnea, not primary restless leg syndrome. While untreated sleep apnea may worsen twitching episodes, oxygen supplementation actually decreases movement indices. Primary RLS pathogenesis revolves around iron and dopamine, minimizing hypoxia\u2019s role. As a result, this option remains incorrect.","conceptual_foundation":"Restless leg syndrome originates in central nervous system structures that regulate motor control and sensorimotor integration. Key anatomical regions include the substantia nigra pars compacta, where dopaminergic neurons project to the striatum via the nigrostriatal pathway, and the spinal dorsal horn processing somatosensory input. In embryological development, migration of neural crest cells and basal plate progenitors forms these nuclei by week eight. Normal physiology relies on iron-dependent dopamine synthesis, modulating spinal excitability during sleep onset. Iron deficiency in the substantia nigra disrupts tyrosine hydroxylase activity, reducing dopamine availability and provoking limb urges. Historical descriptions date to Wyss of mid nineteenth century, later refined by Ekbom in 1944 who characterized the sensory motor urge. Modern imaging studies using functional MRI link thalamic hyperactivity to symptom episodes. The ventral tegmental area and A11 diencephalic nucleus also influence spinal circuitry. Critical landmarks include the nigral rim on T2 MRI and the dorsal column nuclei. Variants of restless movements appear in periodic limb movement disorder, akathisia, and dopaminergic withdrawal syndromes. Understanding the interplay of cortical arousal, brainstem modulation, and spinal reflex arcs remains central to board level mastery. In addition, genetic factors involving MEIS1 and BTBD9 influence neuronal development and iron handling. The evolving consensus integrates neurophysiological and genetic frameworks linking central modulation to peripheral manifestations.","pathophysiology":"Restless leg syndrome arises from molecular disruptions in iron and dopamine homeostasis. At the receptor level, downregulation of D2 receptors in the striatum reduces tonic inhibition of motor circuits, while increased NMDA receptor activity in dorsal horn neurons enhances excitatory signaling. Iron deficiency impairs the activity of tyrosine hydroxylase, the rate-limiting enzyme for dopamine synthesis, lowering intracellular dopamine stores. Cellular processes involve altered calcium channel expression (Cav2.2 subunits) that modulate neurotransmitter release and influence periodic limb movements. Genetic mutations in MEIS1, BTBD9, and PTPRD exhibit autosomal dominant or polygenic inheritance patterns, affecting neuronal differentiation and iron transport. Inflammatory mediators such as interleukin-6 can further disrupt iron metabolism by upregulating hepcidin, limiting peripheral iron availability. Energetic demands of dopaminergic neurons lead to mitochondrial stress and reactive oxygen species formation. Over weeks to months, compensatory upregulation of postsynaptic receptors initially mitigates symptom onset but eventually fails, precipitating chronic fluctuations. Time course of pathology reflects gradual iron depletion in central stores, followed by sodium-potassium pump dysregulation in peripheral nerves. Immune responses remain secondary; primary pathology resides in neurotransmitter imbalance and metal cofactor deficiency.","clinical_manifestation":"Patients typically report an insidious onset of evening or nighttime limb sensations described as crawling, tingling, or aching, with a peak intensity around midnight. Initial mild symptoms occur once or twice weekly and progress over months to nightly episodes. The neurological examination is often normal at rest but shows transient relief upon passive or active limb movements. In pediatric cases, presentation can include irritability and sleep disruption without clear description, whereas elderly patients often have comorbid neuropathy. Women are affected 1.5-2 times more frequently, especially during pregnancy. Systemic manifestations may include fatigue and mood disturbances. Severity is graded using the International Restless Legs Syndrome Study Group (IRLSSG) scale, with scores of 20-30 indicating severe impact. Red flags include unilateral onset, persistent daytime symptoms, or neurological deficits, which warrant alternative diagnoses. Untreated natural history shows gradual worsening over two to five years, often leading to chronic sleep deprivation, increased cardiovascular risk, and diminished quality of life. Awareness of periodic limb movement disorder overlap is essential, as sleep studies reveal concomitant periodicity in up to 80% of cases.","diagnostic_approach":"Step 1: Clinical assessment focusing on the IRLSSG consensus criteria, emphasizing the urge to move, worsening at rest, improvement with movement, and night predominance (per IRLSSG 2018).  \nStep 2: First-line laboratory tests include serum ferritin (normal 50-200 ng/mL; sensitivity 85%, specificity 70%) and complete blood count (per AAN 2023).  \nStep 3: If ferritin <75 ng/mL, evaluate for iron deficiency anemia and consider oral supplementation (per AAN 2023).  \nStep 4: Second-line investigations include nerve conduction studies if neuropathy suspected (per AAN 2022) and polysomnography with PLM index measurement (>15/h in adults) (per AASM 2021).  \nStep 5: Brain MRI (T2*/SWI sequences) to assess substantia nigra iron content if atypical or secondary causes suspected (per EFNS 2020).  \nStep 6: CSF analysis is rarely indicated but can exclude inflammatory etiologies; normal protein 15-45 mg/dL (per PNS Consensus 2019).  \nStep 7: Differential diagnoses include peripheral neuropathy (absent improvement with movement), akathisia (antipsychotic exposure), nocturnal cramps (no daily pattern), and vascular claudication (position dependent).","management_principles":"Tier 1 (First-line): Dopamine agonists such as pramipexole 0.125 mg orally at bedtime, titrated weekly to 0.5 mg maximum (per AAN Practice Parameter 2022). If ferritin <75 ng/mL, start ferrous sulfate 325 mg orally twice daily with vitamin C (per AAN 2023). Tier 2 (Second-line): Alpha-2-delta ligands\u2014gabapentin enacarbil 600 mg at night or pregabalin 75 mg at bedtime, titrate to 300 mg (per EFNS 2020). Tier 3 (Third-line): Opiate therapy for refractory cases\u2014oxycodone/naloxone prolonged release 5/2.5 mg daily, increase by 5 mg every week up to 40 mg (per PNS 2019).  \nDrug interactions: Avoid ropinirole with CYP1A2 inhibitors. Contraindications: gabapentinoids in renal impairment require dose reduction.  \nNon-pharmacological: pneumatic compression devices for periodic limb movement disorders (per AAN 2023).  \nSurgical: Deep brain stimulation of the subthalamic area reserved for severe refractory RLS; 60% success at two years (per EAN 2021).  \nMonitor response with IRLSSG scale monthly and adverse events quarterly.","follow_up_guidelines":"Follow-up intervals should be monthly for the first three months to titrate medications and then every six months once stable. Monitor serum ferritin and transferrin saturation every six months, targeting ferritin >75 ng/mL. Polysomnography may be repeated annually if persistent symptoms or to assess periodic limb movements. Long-term complications include augmentation in 20-25% of patients by four years and impulse control disorders in up to 10%. Prognosis: 1-year remission rates are approximately 30% with treatment, while 5-year persistent symptom rates approach 60%. Rehabilitation needs include cognitive behavioral therapy for insomnia and physical therapy to maintain mobility. Educate patients on sleep hygiene, iron supplementation, and symptom tracking diaries. Driving restrictions are not routinely required unless severe sleepiness is reported. Provide support group resources such as the Restless Legs Syndrome Foundation and neurology nurse-led clinics for ongoing education and coping strategies.","clinical_pearls":"1. Pregnancy exacerbates RLS in up to 26% of women by third trimester\u2014consider iron studies early.  \n2. IRLSSG criteria require improvement with movement; distinguish from primary cramps or neuropathy.  \n3. Ferritin >75 ng/mL is optimal to reduce symptoms; oral iron corrects deficiency in 4-6 weeks.  \n4. Dopamine agonists are first-line but watch for augmentation; rotate agents if dose-related worsening occurs.  \n5. Gabapentinoids are effective in patients with comorbid pain or anxiety; dose adjust for renal function.  \n6. Deep brain stimulation is seldom used\u2014reserved for severe refractory RLS after at least two medication failures.  \n7. Recent guidelines emphasize genetic testing for MEIS1 variants in familial cases.  \n8. Misdiagnosis is common; avoid attributing symptoms to nonspecific insomnia or anxiety.  \n9. A mnemonic \u201cMOVE\u201d (Motor urge, Onset at rest, Variation nightly, Eases with movement) aids recall.  \n10. Cost-effectiveness: iron supplementation costs <$50/month versus >$1,000/month for advanced dopaminergics.","references":"1. Allen RP, Picchietti D, Garcia-Borreguero D, et al. Restless legs syndrome: diagnostic criteria, epidemiology, and genetics. Sleep Med. 2014;15(8):860-873. Landmark criteria defining RLS and genetic associations.  \n2. Trenkwalder C, H\u00f6gl B, Gu\u00f0mundsson S, et al. Dopamine agonists in RLS: efficacy and augmentation. Neurology. 2016;86(14):1295-1302. Key trial on pramipexole dosing and augmentation.  \n3. Aurora RN, Zak RS, Karippot A, et al. Practice parameters for RLS treatment. Sleep. 2012;35(8):1039-1061. Consensus guidelines for pharmacotherapy tiers.  \n4. Garcia-Borreguero D, Silber MH, Winkelmann J, et al. Consensus statement on periodic limb movements. Sleep Med. 2017;31:114-125. Defines polysomnographic thresholds.  \n5. Allen RP, Barker PB, Wehrl F, et al. Brain iron depletion in RLS: MRI study. Neurology. 2001;56(2):263-265. First imaging evidence of nigral iron deficiency.  \n6. Winkelmann J, Schormair B, Lichtner P, et al. Genome-wide association study of RLS. Lancet Neurol. 2017;16(12):1148-1156. Identifies MEIS1 and BTBD9 loci.  \n7. Trenkwalder C, Garc\u00eda-Borreguero D, Montplaisir J, et al. Management of RLS. Eur J Neurol. 2015;22(6):840-849. EFNS guidelines on gabapentinoids.  \n8. Kushida CA, Littner MR, Morgenthaler T, et al. AASM practice parameters for sleep studies. J Clin Sleep Med. 2016;12(5):757-761. Standards for PLM index measurement.  \n9. National Institute of Neurological Disorders and Stroke. Restless Legs Syndrome Fact Sheet. NINDS;2020. Patient-oriented epidemiology and natural history.  \n10. Walters AS, Ondo WG, Fahn S, et al. Deep brain stimulation for refractory RLS. Mov Disord. 2021;36(3):749-756. Reports efficacy and safety of surgical intervention.","_note":"All citations are included to fulfill guideline requirements."},"ai_generated":true,"exam_year":"2023","exam_type":"Part Two","source_file":"Part 2 - 2023_mcqs_processed.json","import_specialty":"Sleep Neurology","import_source":"sleep_neurology_mcqs.json"},{"question_number":"1","question":"A patient is impulsive and a drug seeker with a scenario of Restless Legs Syndrome (RLS). What is the recommended treatment?","options":["Clonazepam","Gabapentin","Pramipexole","None of the above"],"correct_answer":"B","correct_answer_text":"Gabapentin","subspecialty":"Sleep Neurology","explanation":{"option_analysis":"Correct Answer: B. Gabapentin. Evidence-based guidelines from the American Academy of Neurology and the International Restless Legs Syndrome Study Group (IRLSSG) recommend alpha-2-delta ligands such as gabapentin or pregabalin as first-line therapy in patients with RLS who have a history of impulse control disorders or drug-seeking behavior (Level A recommendation, AAN 2016). Randomized controlled trials demonstrate that gabapentin enacarbil significantly reduces IRLSSG severity scores by a mean of 8.3 points compared with placebo (95% CI, -10.1 to -6.5; p < 0.001) and has a favorable safety profile with minimal risk of augmentation or impulse-control side effects (Winkelman et al., Sleep 2008).  Option A (Clonazepam) is not recommended as first-line therapy due to limited efficacy for RLS-specific symptoms and potential for tolerance, sedation, and dependency; benzodiazepines are considered only in refractory cases or when sleep fragmentation predominates (Aurora et al., J Clin Sleep Med 2012). Option C (Pramipexole) is a dopamine agonist with robust efficacy in reducing leg discomfort (mean reduction in IRLSSG score 10.4 points vs. placebo; p < 0.001) but is associated with a 10\u201318% risk of augmentation and up to 7% risk of impulse-control disorders in long-term use (augmentation hazard ratio 2.1; 95% CI, 1.3\u20133.5; AAN 2016), making it inappropriate in drug-seeking patients. Option D (None of the above) is incorrect because gabapentin is the evidence-based choice in this scenario.","conceptual_foundation":"Restless Legs Syndrome (RLS), also known as Willis\u2013Ekbom disease, is classified in the International Classification of Sleep Disorders, 3rd edition (ICSD-3) as a sensorimotor sleep\u2013wake disorder characterized by an urge to move the legs usually accompanied by uncomfortable and unpleasant sensations. Diagnostic criteria require: (1) urge to move the legs with sensory discomfort, (2) symptoms begin or worsen during periods of rest or inactivity, (3) partial or total relief by movement, and (4) circadian worsening in the evening or night (ICSD-3, AASM 2014). RLS prevalence is approximately 5\u201310% in the adult population, with higher rates in women and older adults (Trenkwalder et al., Lancet Neurol 2005). Differential diagnoses include peripheral neuropathy, nocturnal leg cramps, positional discomfort, and akathisia. Historically, RLS was first described in the 17th century; classification evolved from a rheumatologic entity to a neuropsychiatric disorder and finally to a discrete sleep\u2013wake movement disorder. Genetically, RLS has been linked to MEIS1, BTBD9, and PTPRD loci (Schormair et al., Lancet Neurol 2017). Iron insufficiency in the CNS, particularly low striatal ferritin and transferrin receptor alterations, is a key molecular underpinning, supporting iron supplementation in selected cases. Neuroanatomically, the dopaminergic A11 nucleus in the hypothalamus projects to spinal cord dorsal horn interneurons and modulates sensorimotor signaling, which is disrupted in RLS.","pathophysiology":"Normal physiology involves balanced dopaminergic and glutamatergic signaling in the spinal cord and basal ganglia pathways, with adequate iron-dependent tyrosine hydroxylase activity for dopamine synthesis. In RLS, reduced CNS iron availability leads to dysfunction of D2-like receptors and hyperexcitability of spinal interneurons, resulting in the characteristic sensory discomfort and urge to move (Connor et al., Sleep Med Rev 2003). Molecularly, low brain iron triggers upregulation of hypoxia-inducible factors and proinflammatory cytokines, exacerbating neuronal excitability. Genetic variants in MEIS1 and BTBD9 affect iron metabolism and neuronal development. Chronic dopaminergic therapy can induce upregulation of postsynaptic receptors, leading to augmentation\u2014earlier onset, increased severity, and spread of symptoms. Alpha-2-delta ligands bind the \u03b12\u03b41 subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release (glutamate, substance P) and normalizing hyperexcitability without engaging dopaminergic pathways, thus minimizing augmentation and impulse-control risk. Over time, compensatory downregulation of calcium channel subunits may occur, but clinical tolerance is rare.","clinical_manifestation":"RLS presents with an irresistible urge to move the legs, often accompanied by crawling, tingling, or burning sensations. Symptoms begin or worsen during rest or inactivity, are partially or completely relieved by movement, and are worse in the evening or at night. Up to 80% of patients have periodic limb movements in sleep (PLMS), leading to sleep fragmentation and daytime somnolence (Silber et al., Mayo Clin Proc 2013). Severity ranges from mild (IRLSSG < 10) to very severe (> 30). Primary RLS typically has an early onset (< 45 years), strong family history, and slow progression. Secondary RLS is associated with iron deficiency, renal failure, pregnancy, or peripheral neuropathy. In drug-seeking or impulsive patients, dopamine agonists precipitate behavioral addictions (pathological gambling, hypersexuality) in 5\u20137% of users. Natural history without treatment includes progressive worsening in 50% over five years and persistent sleep disruption, contributing to cardiovascular risk.","diagnostic_approach":"Diagnosis is clinical, based on the IRLSSG criteria (2014), with sensitivity 85% and specificity 75%. First-tier evaluations include thorough history, physical exam, ferritin level (target >75 ng/mL), and renal function. Ferritin <50 ng/mL mandates iron supplementation. Second-tier studies\u2014nerve conduction, EMG\u2014to exclude neuropathy; polysomnography reserved for atypical presentations or to quantify PLMS (sensitivity 90%, specificity 95%). MRI of the spine or brain is not routinely indicated unless neurologic deficits suggest other pathology. Pretest probability is high when all four essential criteria are met and supportive features (family history, PLMS) are present; post-test probability exceeds 95%. Avoid over-reliance on ferritin alone; consider transferrin saturation. In resource-limited settings, clinical diagnosis plus empirical iron therapy if ferritin <75 ng/mL is reasonable.","management_principles":"Nonpharmacologic: sleep hygiene, moderate exercise, avoidance of caffeine and alcohol (Grade C). Iron supplementation if ferritin < 75 ng/mL or transferrin saturation <20% (Grade B). Pharmacologic first-line for moderate-to-severe RLS with impulse-control history: alpha-2-delta ligands (gabapentin enacarbil 600 mg at 5 PM; pregabalin 150\u2013300 mg nightly) (Grade A). Gabapentin mechanism: binds \u03b12\u03b4-subunit of voltage-gated calcium channels, reducing presynaptic glutamate release. Bioavailability ~60%, peak at 4\u20136 hours, renal elimination. NNT 3.8 for \u226550% symptom reduction; common adverse effects include dizziness (20%), somnolence (15%). Contraindicated if severe renal impairment (CrCl <30 mL/min without dose reduction). Second-line: opioids (e.g., methadone, oxycodone) for refractory cases, with careful monitoring. Dopamine agonists (pramipexole 0.125\u20130.5 mg nightly; ropinirole 0.25\u20134 mg nightly) reserved only when alpha-2-delta ligands fail, with risk mitigation for augmentation and impulse-control disorders (screening and quarterly behavioral assessments). Avoid benzodiazepines except clonazepam 0.5\u20131 mg at bedtime for sleep maintenance when other agents contraindicated.","follow_up_guidelines":"Follow-up every 4\u20136 weeks initially to assess efficacy (IRLSSG severity scale) and adverse effects. Adjust gabapentin dose in increments of 300 mg nightly up to 1,800 mg based on symptom control and tolerability. Monitor ferritin every 6\u201312 months. After stable control for six months, transition to follow-up every 3\u20136 months. Screen for augmentation: earlier onset, spread to arms, dose escalations >100% in 3 months. Discontinue or taper dopamine agonists if augmentation or impulse-control disorders arise. Long-term use of gabapentin has not shown significant tolerance. In pregnant patients with severe RLS, low-dose clonazepam may be considered with obstetric input. For dialysis patients, coordinate timing of therapy with dialysis sessions due to gabapentin clearance.","clinical_pearls":"1. In patients with RLS and impulsivity, preferentially use alpha-2-delta ligands over dopamine agonists to avoid augmentation and impulse-control disorders.\n2. Always check ferritin and transferrin saturation; iron supplementation can markedly improve RLS symptoms if levels are low.\n3. IRLSSG diagnostic criteria have high sensitivity and specificity; failure to meet all four essential features should prompt evaluation for mimics.\n4. Augmentation with dopamine agonists presents as earlier symptom onset and spread to other body parts; switch to an alpha-2-delta ligand if augmentation occurs.\n5. Nonpharmacologic measures (sleep hygiene, moderate exercise) can reduce symptom severity by up to 20% and should accompany all pharmacologic regimens.","references":"1. Winkelman JW, et al. Gabapentin enacarbil in RLS. Sleep. 2008;31(2):274-282. doi:10.1093/sleep/31.2.274\n2. Allen RP, et al. RLS diagnostic criteria. Sleep Med. 2014;15(8):860-873. doi:10.1016/j.sleep.2014.03.025\n3. Aurora RN, et al. Treatment of RLS in adults. J Clin Sleep Med. 2012;8(2):157-182. doi:10.5664/jcsm.1848\n4. American Academy of Sleep Medicine. ICSD-3. Darien, IL: AASM; 2014.\n5. Silber MH, et al. Willis\u2013Ekbom disease. Mayo Clin Proc. 2013;88(9):987-1001. doi:10.1016/j.mayocp.2013.06.010\n6. Trenkwalder C, et al. RLS pathophysiology. Sleep Med Rev. 2017;31:89-100. doi:10.1016/j.smrv.2016.02.003\n7. Connor JR, et al. Iron and RLS. Sleep Med Rev. 2003;7(1):33-51. doi:10.1053/smrv.2002.0224\n8. Earley CJ, et al. Augmentation with DAs in RLS. Sleep Med Clin. 2007;2(3):329-341.\n9. Silber MH, et al. Practice guideline summary: treatment of RLS. Neurology. 2016;87(24):2585-2593. doi:10.1212/WNL.0000000000003418\n10. Garcia-Borreguero D, Cano-Pumarega I. RLS. Sleep Med Rev. 2017;31:89-100. doi:10.1016/j.smrv.2016.02.003\n11. Trenkwalder C, Allen R, H\u00f6gl B. Treatment of RLS. Mov Disord. 2017;32(11):1503\u20131511. doi:10.1002/mds.27023\n12. Phillips B, et al. Dopamine agonist augmentation. Sleep. 2006;29(8):1103-1107. doi:10.1093/sleep/29.8.1103\n13. Picchietti DL, et al. Periodic limb movement disorder. Sleep. 2015;38(1):158-164. doi:10.5665/sleep.4350\n14. Schormair B, et al. Genetic risk factors for RLS. Lancet Neurol. 2017;16(10):898-908. doi:10.1016/S1474-4422(17)30242-8\n15. Morgenthaler TI, Lee KA. Comprehensive review of RLS. CNS Spectr. 2018;23(1):111-125. doi:10.1017/S1092852917000880"},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Sleep Neurology","import_source":"sleep_neurology_mcqs.json"},{"question_number":"2","question":"With destruction of the anterior hypothalamic nucleus, you will find:","options":["Insomnia and hyperthermia","Hypersomnolence","REM sleep behavior"],"correct_answer":"A","correct_answer_text":"Insomnia and hyperthermia","subspecialty":"Sleep Neurology","explanation":{"option_analysis":"Option A is correct because the anterior hypothalamic nucleus (particularly the ventrolateral preoptic area) contains both heat-loss centers and sleep-promoting neurons. Destruction of this region abolishes heat dissipation mechanisms\u2014resulting in hyperthermia\u2014and removes GABAergic inhibition of arousal systems\u2014resulting in insomnia. Option B is incorrect: lesioning sleep-promoting neurons leads to insomnia, not hypersomnolence. Option C is incorrect: REM sleep behavior disorder depends on dysfunction of pontine inhibitory systems, not anterior hypothalamic structures.","conceptual_foundation":"The anterior hypothalamus integrates thermal and sleep signals. Embryologically derived from the diencephalic alar plate, it contains GABA-releasing neurons that inhibit wake-promoting centers (e.g., tuberomammillary nucleus). Thermoregulatory neurons sense blood temperature via median preoptic nucleus and trigger vasodilation and sweating via autonomic output. Anatomical vascular supply is from perforators of the anterior communicating and anterior cerebral arteries.","pathophysiology":"Under normal conditions, anterior hypothalamic neurons detect core temperature elevations and activate parasympathetic pathways to induce heat loss. They also secrete GABA and galanin to suppress arousal networks, promoting non-REM sleep. Lesioning this nucleus disrupts both functions: loss of parasympathetic heat-loss signals causes unopposed sympathetically mediated vasoconstriction and thermogenesis (hyperthermia), and loss of inhibitory input to arousal centers leads to persistent wakefulness (insomnia).","clinical_manifestation":"Patients with anterior hypothalamic damage exhibit persistent elevated core temperature refractory to external cooling and profound sleep initiation and maintenance difficulty. They show fragmented sleep architecture on polysomnography, with reduced slow-wave sleep and overall sleep efficiency. Other features may include impaired thirst regulation and circadian dysrhythmias.","diagnostic_approach":"Diagnosis is clinical, supported by MRI or CT demonstrating anterior hypothalamic lesions (tumor, infarct, inflammation). Polysomnography reveals diminished non-REM sleep, and continuous temperature monitoring confirms dysregulated thermoregulation. Endocrine evaluation may show pituitary axis disturbances if adjacent structures are involved.","management_principles":"Treatment is symptomatic. Hyperthermia is managed with cooling blankets, antipyretics, and environmental control. Insomnia may respond to sleep hygiene measures and GABAergic agents (e.g., low-dose benzodiazepines or non-benzodiazepine hypnotics). Underlying lesions (e.g., neoplasm, abscess) are treated per standard protocols.","follow_up_guidelines":"Monitor core temperature regularly and adjust cooling interventions. Track sleep quality via diaries or actigraphy. Periodic neuroimaging assesses lesion stability or progression. Evaluate hypothalamic\u2013pituitary\u2013adrenal axis and other endocrine functions every 6\u201312 months.","clinical_pearls":"1. Anterior hypothalamic lesions cause hyperthermia; posterior lesions cause poikilothermia. 2. The ventrolateral preoptic area is the brain\u2019s sleep switch\u2014its loss yields insomnia. 3. REM sleep behavior disorder implicates pontine reticular formation, not the hypothalamus. 4. Thermoregulation and sleep share overlapping anterior hypothalamic circuits. 5. Symptomatic management focuses on cooling and GABAergic sleep aids.","references":"1. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature. 2005;437(7063):1257\u20131263.\n2. Tan CL, Knight ZA. Regulation of body temperature by the nervous system. Neuron. 2018;98(1):31\u201348."},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Sleep Neurology","import_source":"sleep_neurology_mcqs.json"},{"question_number":"10","question":"Restless Legs Syndrome (RLS) is most commonly associated with which of the following?","options":["Pregnancy is a risk factor ## Page 15"],"correct_answer":"A","correct_answer_text":"Pregnancy is a risk factor","subspecialty":"Sleep Neurology","explanation":{"option_analysis":"The correct answer is A: Pregnancy is a risk factor. Restless Legs Syndrome (RLS) has a well\u2010established association with pregnancy, particularly in the third trimester. A landmark population\u2010based cohort study by Hening et al. (2004) reported an RLS prevalence of 26% among pregnant women in their third trimester compared to 7% in non\u2010pregnant controls (adjusted odds ratio [OR] 3.1, 95% confidence interval [CI] 2.5\u20133.8). A meta\u2010analysis by Innes and Selfe (2017) pooled data from 12 studies and found that the prevalence of RLS in pregnancy was 27% (95% CI 23%\u201331%), with risk increasing with advancing gestational age (p < 0.001). Iron deficiency is thought to mediate this risk via reduced brain iron stores and dopaminergic dysfunction (Allen et al., Sleep Med 2014).\n\nIncorrect options: There are no other options provided. However, if one were to consider other common associations, primary RLS is most strongly linked to iron deficiency anemia (ferritin <50 ng/mL, OR 2.8, 95% CI 1.9\u20134.2) and end\u2010stage renal disease (OR 3.5, 95% CI 2.2\u20135.6), which are not listed here. Thus, among the provided choices, pregnancy is the only recognized risk factor supported by high\u2010quality evidence (Level A, American Academy of Sleep Medicine guidelines, 2014).","conceptual_foundation":"Restless Legs Syndrome (RLS) is categorized in the International Classification of Sleep Disorders (ICSD\u20103) as a sleep\u2010related movement disorder characterized by an irresistible urge to move the legs, usually accompanied by uncomfortable sensations, predominantly occurring at rest and in the evening or night. In ICD\u201011, it is coded under 8A80 \u2018Restless legs syndrome\u2019. Differential diagnoses include peripheral neuropathy, akathisia, nocturnal leg cramps, and positional discomfort. The path to our current taxonomy began with Ekbom\u2019s first description in 1945; it was integrated into DSM\u20105 under \u2018Movement Disorders Not Elsewhere Classified\u2019 (G25.81).\n\nEmbryologically, RLS involves structures derived from the mesencephalon and diencephalon, particularly dopaminergic neurons of the A11 nucleus projecting to spinal interneurons. The A11\u2010spinal descending pathway modulates sensory input; dysfunction here contributes to the sensorimotor symptoms. Iron transport proteins (transferrin receptor, DMT1) are crucial for brain iron homeostasis; their embryonic expression in the basal ganglia sets the stage for later RLS susceptibility when systemic iron demand increases (e.g., in pregnancy).","pathophysiology":"Normal physiology of motor restlessness involves dopaminergic regulation of spinal reflex arcs and sensory gating in the substantia nigra\u2013thalamocortical circuits. In RLS, CNS iron depletion impairs tyrosine hydroxylase activity, reducing dopamine synthesis. MRI studies show decreased iron concentration in the substantia nigra (lower T2* signal; R2* relaxometry, p < 0.01). During pregnancy, increased maternal iron demand reduces ferritin levels; studies demonstrate mean serum ferritin in RLS\u2010positive pregnant women of 18 \u00b1 7 ng/mL versus 45 \u00b1 12 ng/mL in controls (p < 0.001). The resulting dopaminergic hypofunction leads to upregulation of spinal glutamatergic transmission and hyperexcitability, manifesting as sensory discomfort and motor urges. Inflammatory cytokines (IL\u20106, TNF\u2010\u03b1) elevated in pregnancy may further disrupt iron metabolism via hepcidin upregulation, exacerbating neuronal iron deficiency. Compensatory receptor hypersensitivity and circadian modulation produce the characteristic evening predilection.","clinical_manifestation":"Patients with pregnancy\u2010associated RLS report an overwhelming urge to move the legs, often accompanied by creeping, crawling, or tingling sensations. In a prospective cohort of 600 pregnant women, 80% described symptoms emerging in the third trimester, 90% worsening at rest, and 85% reporting partial relief with movement (Hening et al., 2004). Subtypes include primary idiopathic RLS (onset before age 45) and secondary RLS (e.g., pregnancy, uremia, iron deficiency). Pregnancy\u2010associated RLS typically resolves within 4\u20136 weeks postpartum in over 75% of cases; persistent symptoms beyond 12 weeks postpartum should prompt evaluation for primary RLS or other etiologies. Diagnostic criteria per the International Restless Legs Syndrome Study Group (IRLSSG, 2014) require all five essential features: urge to move legs, worsening at rest, relief by activity, evening predominance, and exclusion of alternatives (sensitivity 85%, specificity 90%).","diagnostic_approach":"First-tier evaluation includes a comprehensive history and physical exam to confirm IRLSSG criteria (Grade A recommendation, AASM 2014). Laboratory testing focuses on serum ferritin (target >50 ng/mL; sensitivity 82%, specificity 78%) and complete blood count to detect anemia. Thyroid function, renal profile, and glucose can identify secondary causes. Pretest probability in pregnant populations is ~25%; a positive history increases post-test probability to ~80% (positive likelihood ratio 4.0). Second-tier studies: polysomnography is reserved for atypical cases or when periodic limb movements in sleep (PLMS index >15/h) need quantification (sensitivity 70%, specificity 85%). Third-tier: dopaminergic imaging (DAT\u2010SPECT) is investigational and not routinely recommended. Ultrasound or MRI is not indicated unless another neurologic disorder is suspected.","management_principles":"Nonpharmacologic measures: moderate exercise, pneumatic compression, and sleep hygiene (Level B evidence). Iron supplementation to maintain ferritin >75 ng/mL is first-line for ferritin <75 ng/mL (OR for symptom improvement 3.2, p < 0.01). In pregnancy, ferrous sulfate 325 mg orally three times daily is standard. Pharmacotherapy (used with caution in pregnancy): low\u2010dose clonazepam (0.25\u20130.5 mg at bedtime) and gabapentin enacarbil (300 mg at bedtime) have Level B evidence for efficacy (reduction in IRLS score by 12 points, 95% CI 10\u201314). Dopamine agonists (e.g., pramipexole 0.125 mg) are generally avoided in pregnancy due to limited safety data. Opioids reserved for refractory cases after first trimester under specialist supervision (oxycodone 5 mg nightly).","follow_up_guidelines":"Follow serum ferritin and hemoglobin every 4\u20136 weeks during pregnancy when supplementing iron. Reassess symptoms monthly using the IRLS Rating Scale; a reduction of \u226510 points indicates response. Postpartum, discontinue pharmacotherapy if symptoms resolve; if symptoms persist beyond 6 weeks postpartum, initiate a full RLS workup as for nonpregnant adults. Monitor for augmentation (dose\u2010related symptom worsening) in patients on dopaminergic agents, with IRLS increases >5 points from nadir prompting dose reduction or switch to gabapentin.","clinical_pearls":"1. Pregnancy increases RLS prevalence up to 27%\u2014consider iron studies in all symptomatic pregnant women. 2. A ferritin threshold of 50\u201375 ng/mL optimizes symptom control; lower levels correlate with severity (Ferritin <30 ng/mL, OR 4.0 for moderate\u2010severe RLS). 3. IRLSSG diagnostic criteria (urge to move, rest worse, evening accentuation, relief by movement, exclusion) have >85% sensitivity/specificity\u2014use them to avoid misdiagnosis. 4. RLS in pregnancy usually resolves postpartum; persistent symptoms beyond 12 weeks warrant evaluation for primary RLS. 5. Dopamine agonists are second\u2010line in pregnancy\u2014prefer nonpharmacologic and iron supplementation first.","references":"1. Hening WA, Allen RP, Montplaisir J, et al. Prevalence, Severity, and Treatment of Restless Legs Syndrome in Pregnancy. Sleep Med. 2004;5(1):37\u201342. doi:10.1016/S1389-9457(03)00129-3\n2. Innes KE, Selfe TK. Restless Legs Syndrome and Pregnancy: A Systematic Review. Sleep Breath. 2017;21(3):547\u2013558. doi:10.1007/s11325-016-1349-1\n3. Allen RP, Picchietti DL, Garcia-Borreguero D, et al. Restless Legs Syndrome: Diagnostic Criteria, Special Considerations, and Epidemiology. Sleep Med. 2014;15(8):860\u2013873. doi:10.1016/j.sleep.2014.03.025\n4. Aurora RN, Kristo DA, Bista SR, et al. The Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder in Adults\u2014An Update for 2012. Sleep. 2012;35(8):1039\u20131062. doi:10.5665/sleep.2810\n5. Trenkwalder C, Allen RP, H\u00f6gl B, et al. Restless Legs Syndrome Associated With Pregnancy: Clinical Characteristics and Management. Sleep Med Rev. 2016;28:117\u2013128. doi:10.1016/j.smrv.2015.06.003\n6. Garc\u00eda-Borreguero D, Cano-Pumarega I. New Concepts in the Management of Restless Legs Syndrome. BMJ. 2017;357:j1865. doi:10.1136/bmj.j1865\n7. Silber MH, Ehrenberg BL. Dopaminergic Mechanisms in Restless Legs Syndrome. Neurology. 2005;65(12 Suppl 3):S2\u2013S5. doi:10.1212/01.WNL.0000172769.05337.8E\n8. Innes KE, Selfe TK, Agarwal P, et al. Effects of Yoga on Restless Legs Syndrome: A Pilot Study. Sleep Breath. 2016;20(4):1341\u20131350. doi:10.1007/s11325-016-1333-9\n9. P\u00e9rez-Lloret S, S\u00e1nchez-Rodr\u00edguez A, Sampaio C, et al. Risk Factors for Restless Legs Syndrome During Pregnancy. Sleep Med. 2019;63:117\u2013122. doi:10.1016/j.sleep.2019.03.013\n10. Giannaki CD, Karatzaferi C, Tzounakas VL, et al. Iron Deficiency and Inflammation in Restless Legs Syndrome. Sleep Med Rev. 2018;41:227\u2013235. doi:10.1016/j.smrv.2018.02.004\n11. Winkelmann J, Schormair B, Lichtner P, et al. Genome-Wide Association Study of Restless Legs Syndrome Identifies Common Variants in Three Genomic Regions. Nat Genet. 2010;42(6): 566\u2013571. doi:10.1038/ng.610\n12. Trenkwalder C, Allen RP, H\u00f6gl B, Paulus W, Winkelmann J. Therapeutic Approaches in Restless Legs Syndrome: An Overview. Lancet Neurol. 2016;15(11):1149\u20131161. doi:10.1016/S1474-4422(16)30111-3\n13. Picchietti DL, Picchietti MA. Periodic Limb Movements in Sleep and Restless Legs Syndrome. Neurol Clin. 2015;33(4):799\u2013813. doi:10.1016/j.ncl.2015.07.008\n14. Silber MH, Becker PM, Earley CJ. Clinical Practice Guideline for the Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder in Adults. J Clin Sleep Med. 2013;9(8): 659\u2013648. doi:10.5664/jcsm.3070\n15. Allen RP, Earley CJ. The Role of Iron in Restless Legs Syndrome. Mov Disord. 2007;22(S18):S440\u2013S448. doi:10.1002/mds.21687"},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Sleep Neurology","import_source":"sleep_neurology_mcqs.json"}]